Neuroendocrine Tumors in Real Life

Approaches NETs from the perspective of clinical experience

Describes numerous clinical cases to illustrate all possible scenarios in terms of clinical presentation and course

Provides evidence-based guidance on prognosis, diagnosis, and treatment

Approaches NETs from the perspective of clinical experience Describes numerous clinical cases to illustrate all possible scenarios in terms of clinical presentation and course Provides evidence-based guidance on prognosis, diagnosis, and treatment

Auteur

Annamaria Colao , is Full Professor at Federico II University of Naples and Chief of the Neuroendocrine Unit, University Federico II, Naples, Italy. Her current areas of research include the molecular basis and clinical treatment of neuroendocrine tumors and tumors in the hypothalamus/pituitary region, consequences of deficiency and excess of GH and IGF-I for the cardiovascular system, endocrine consequences in survivors of malignant neoplasia, and insulin resistance and cancer. Dr. Colao is a member of numerous medical societies, including the Italian Society of Endocrinology, the European Neuroendocrine Association, and the European Society of Endocrinology. She is the author of more than 500 peer-reviewed publications.

Antongiulio Faggiano , MD, PhD, graduated in Medicine, magna cum laude, at the Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy, in 1997. He became a postgraduate fellow in E ndocrinology in 2002 at the Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples and in 2003 completed his European University Research Diploma in Clinical Oncology (DUERCC) at the Paris-SUD University, Paris, France. He obtained his PhD in Molecular Oncology and Endocrinology in 2007. Dr. Faggiano is the author of about 100 publications in international peer-reviewed journals. Wouter W. de Herder , is a Professor of Endocrine Oncology at the Erasmus MC in Rotterdam, the Netherlands. He is currently the head of endocrinology education at University Hospital. He is also chairman of a multidisciplinary group for endocrine oncology in the Erasmus MC (tumorwerkgroep endocriene tumoren) and head of the ENETS Centre of Excellence for Neuroendocrine Tumors. His research focuses on neuroendocrine and adrenal tumors and Cushing's syndrome. Dr. de Herder is a member of several international and Dutch national societies; he se rves on the board of the Dutch society for Endocrinology (NVE), is a member of the Endocrine Society (USA), Society for Endocrinology (UK), Pituitary Society (USA), European Society of Endocrinology (ESE), and European Neuroendocrine Association (ENEA). He served as chairman and vice-chairman of ENETS (European Neuroendocrine Tumour Society). Dr. de Herder serves on the advisory boards of both ENETS and NANETS (North American Neuroendocrine Tumor Society). He is a member of the educational committee of the European Society of Endocrinology (ESE). Dr. de Herder has published 90 invited presentations at Dutch national and international meetings.

Contenu
Part I General Remarks: Epidemiology of NET (by site of tumour and by geographical area).- Pathological classification (GEP, TNET and rare forms).-Biology of NET (oncogenes, tumor suppressor genes, epigenetics).- Part II Clinical Cases and Their Implications (from clinical practice to guidelines): Prognostic factors: TNM.- Grading (Ki67 score).- Molecular pathway - somatostatin receptors.- Molecular pathway - oncogene (mTOR).- Molecular pathway - tumor suppressor gene (MEN1).- Nuclear medicine imaging (FDG-PET).- Nuclear medicine imaging (Octreoscan / gallium PET).- Diagnosis: Tumor detection in syndromic NET (carcinoid syndrome).- Tumor detection in syndromic NET (ZES).- Tumor detection in syndromic NET (hypoglycemic hyperinsulinemic syndrome).- Tumor detection in incidentally detected non-functioning NET.- Tumor staging (stomach/duodenum, colon/rectum).- Tumor staging (bronchi).- Tumor staging (il eum).- Tumor staging (pancreas).- Therapy: Locoregional disease (stomach).- Locoregional disease (pancreas).- Locoregional disease (ileum).- Locoregional disease (appendix).- Locoregional disease (bronchi).- Metastatic disease (stomach).- Metastatic disease (pancreas).- Metastatic disease (ileum).- Metastatic disease (appendix).- Metastatic disease (bronchi.- Metastatic disease with unknown primary tumour. <p